PSTV Form 4/A: 1.38M Options, 459,878 RSUs Awarded to CFO
Rhea-AI Filing Summary
PLUS THERAPEUTICS, INC. (PSTV) disclosure shows an amendment to an insider Form 4 for Andrew Sims, the company's Chief Financial Officer, correcting previously reported vesting terms. On 08/13/2025 Mr. Sims was awarded 1,379,636 stock options with an exercise price of $0.5744 and 459,878 restricted stock units (RSUs). The options vest over four years in equal monthly 1/48th installments and expire 08/12/2035. The amended RSU disclosure clarifies they vest over twelve quarters in substantially equal 1/12th increments beginning with the quarter ended 09/30/2025 and convert one-for-one into common shares upon vesting. The filing is signed by Mr. Sims on 10/03/2025.
Positive
- Grant clarity: Amendment clarifies RSU vesting to 12 quarters starting 09/30/2025
- Long-term alignment: Options vest over 4 years, aligning CFO incentives with multi-year performance
Negative
- Potential dilution: 1,379,636 options and 459,878 RSUs could increase outstanding shares if fully vested and exercised
- Concentration of equity: Large single-officer grants may materially affect share count depending on company size
Insights
Amendment clarifies executive compensation vesting schedule; no cash transaction disclosed.
The filing corrects the RSU vesting cadence for CFO Andrew Sims, specifying quarterly vesting over 12 quarters beginning 09/30/2025. This provides clearer timelines for when equity may convert to common shares and become freely tradable.
Because the report shows grants (options and RSUs) rather than sales, the immediate dilution impact is prospective and tied to vesting schedules and exercise activity; the options total 1,379,636 and RSUs total 459,878.
Large option and RSU grants create potential future dilution if fully vested and exercised.
The option award of 1,379,636 shares and RSUs of 459,878 represent specific share counts that will add to outstanding shares only as they vest and, for options, if exercised at $0.5744. The options vest over four years and expire 08/12/2035, while RSUs vest over 12 quarters.
This establishes explicit timelines for share issuance; investors can use these dates to model potential dilution and timing of insider-aligned incentives.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 1,379,636 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 459,878 | $0.00 | -- |
Footnotes (1)
- The options vest over four years in equal 1/48th increments on each monthly anniversary of the issuance. This amendment is being filed to correct a Form 4 filed on August 15, 2025, which inadvertently disclosed the incorrect vesting terms of the Restricted Stock Units ("RSUs"). The RSUs awarded on August 13, 2025 vest over twelve quarters, vesting in substantially equal 1/12th increments beginning with the quarter ended September 30, 2025. The RSUs convert into shares of Common Stock upon vesting on a one for one basis.
